Health Care/Hospital
Insilico Medicine Announces First-in-Human Study for Orally PHD Inhibitor ISM5411 for Inflammatory Bowel Disease (IBD)
* ISM5411 is an oral, PHD-specific inhibitor that facilitates the treatment of IBD by inducing the expression of gut barrier protective genes. * ISM5411 is Insilico Medicine's fifth AI-driven drug program to enter clinical trials, with the first dose of healthy subjects completed inAustralia. ...
2023-12-05 06:00
1441
Ubie's AI Symptom Checker Used by 2 Million Americans in First Year, Fueling Pharma Partnerships
Ubie, a trailblazing AI-driven healthcare company, has achieved a new milestone with its AI Symptom Checker, surpassing 2 million uses in the U.S. in just over a year. Leveraging this expanding user engagement, Ubie is advancing its partnerships with pharmaceutical companies to promote early dise...
2023-12-05 00:00
1219
Pioneering health innovations at China Int'l Supply Chain Expo
BEIJING, Dec. 4, 2023 /PRNewswire/ -- This is a report from China.org.cn about health innovations at China Int'l Supply Chain Expo:   At a dental clinic at the China Int'l Supply Chain Expo, you can take advantage of a free dental check. The 360° view allows you to see all a...
2023-12-04 22:20
1142
CARsgen's CT071 Received IND Clearance from the FDA for Treating Relapsed/Refractory Multiple Myeloma or Relapsed/Refractory Primary Plasma Cell Leukemia
SHANGHAI, Dec. 4, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the U.S. Food and Drug Administration (FDA) has granted Investiga...
2023-12-04 21:50
1142
Technoderma Medicines Completes Phase 1 Dose Escalation Clinical Trial of TDM-180935 for Atopic Dermatitis
CHENGDU, China, Dec. 4, 2023 /PRNewswire/ -- Technoderma Medicines, Inc. ("the Company"), a clinical stage biopharmaceutical company, is pleased to report that the Company has completed a Phase 1 clinical trial (NCT05525468) of TDM-180935 topical ointment for Atopic Dermatitis (AD). This first cl...
2023-12-04 21:13
1144
Abbisko Therapeutics Announced the Entry into a Licensing Agreement for Pimicotinib (ABSK021) with Merck
SHANGHAI, Dec. 4, 2023 /PRNewswire/ -- On 4 Dec. 2023, Abbisko Therapeutics announced that it has entered into a licensing agreement with Merck, a leading science and technology company headquartered in Darmstadt,Germany. Under the terms of the agreement, Merck will be granted an exclusive licens...
2023-12-04 21:05
1082
Crystal Pharmatech's CDMO Business Unit successfully passed the dual certification of GMP and GDP conducted by SGS
SUZHOU, China, Dec. 4, 2023 /PRNewswire/ -- Recently, Crystal Pharmatech's CDMO Business Unit - Crystal Formulation Services (CFS) successfully obtained dual certification in Good Manufacturing Practices (GMP)[1] and Good Distribution Practices (GDP)[2] from SGS, an internationally recognized thi...
2023-12-04 21:00
1017
Mootral introduces new methane reduction technology, doubling efficacy using a well-known natural molecule
Mootral's new platform reduces methane emissions from cows by 50% and can be delivered to both housed and grazing cattle, vastly increasing the opportunity to reduce methane emissions globally LONDON, Dec. 4, 2023 /PRNewswire/ -- Mootral, a British biotech company, announces it has completed the...
2023-12-04 20:00
1476
Latest Updates of Viva's Portfolio Companies
HONG KONG, Dec. 4, 2023 /PRNewswire/ -- Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term development. This continuous innovation keeps companies up to date and promotes the evolution of R&D and the succ...
2023-12-04 17:55
1466
Cigna Healthcare Research: People in Hong Kong Have the Lowest Vitality Score in APAC
Majority Desire Support from Employer for Healthier Life * Average vitality score in Hong Kong is lowest in APAC and is significantly lower than the global average * Only one in 20 people in Hong Kong (5%) reported high levels of vitality, compared to close to one in five globally (17%) * ...
2023-12-04 17:34
1310
Supercell Acquires Exclusive Licensing from Japanese Immunotherapy Leader for Advanced NK Cell Treatment Technology
TAIPEI, Dec. 4, 2023 /PRNewswire/ -- Supercell Biotechnology Corporation commemorates the first anniversary of rebranding from previously-called SinoCell Technologies, due to the company's capital increase by RMT Holding Group. Demonstrating the strategic move at the Healthcare+ Expo Taiwan, the...
2023-12-04 16:39
1360
MeltMed® Rings in the Holidays with Reduced Pricing and New NAD+ Starter Packs
* Begin your Wellness Journey with Regenerate Starter Packs;
* Scientifically formulated to maximise effectiveness of NAD supplement;
* Enjoy savings of 50% NEW YORK, Dec. 4, 2023 /PRNewswire/ -- MeltMed
2023-12-04 15:01
1415
First Patient Dosed in Phase Ⅲ Study of JSKN003 for the Treatment of Advanced HER2-Low Breast Cancer
SUZHOU, China, Dec. 4, 2023 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced the first patient has been dosed in the phase III clinical study (JSKN003-302) of anti-HER2 bispecific antibody-drug conjugate JSKN003 for treatment of advanced HER2-low breast cancer. Breast cancer is ...
2023-12-04 14:51
1347
Nona Biosciences Announces Collaboration Agreement with Lycia Therapeutics
CAMBRIDGE, Mass., Dec. 3, 2023 /PRNewswire/ -- Nona Biosciences, a global pioneer of technology innovation and antibody discovery and development solutions, announced today it has entered into a collaboration agreement with Lycia Therapeutics, a leader in extracellular protein degradation. Lycia...
2023-12-04 13:19
1087
First Patient Dosed in European Named Patient (Early Access) Program for TLX250-CDx, Telix's Kidney Cancer Imaging Agent
MELBOURNE, Australia and LIÉGE, Belgium, Dec. 4, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in a named patient (early access) program inthe Netherlands for its investigational positron emission tomography...
2023-12-04 13:00
1264
VISTA Eye Specialist introduces CLEAR - a new generation eye surgery to help patients be glasses free again.
PETALING JAYA, Malaysia, Dec. 4, 2023 /PRNewswire/ -- VISTA Eye Specialist (VISTA) proudly announces the successful introduction of CLEAR (Corneal Lenticule Extraction for Advanced Refractive Correction), an advanced version of the Lenticule Extraction treatment used to correct Short-sightedness ...
2023-12-04 09:38
1291
The 3rd International Medical Innovation and Cooperation Forum convenes in Fangchenggang
Enhancing Global Medical Collaboration and Advancing Shared Development through Inclusive Exchange BEIJING, Dec. 4, 2023 /PRNewswire/ -- On 26 November, the 3rd International Medical Innovation and Cooperation Forum was held in Fangchenggang, Guangxi Zhuang Autonomous Region,China. The forum, ...
2023-12-04 08:59
1736
Everest Medicines Announces Investigational New Drug Application Acceptance of Zetomipzomib in China
-- Everest plans to contribute to the ongoing global Phase 2b PALIZADE trial of zetomipzomib in active lupus nephritis – -- Zetomipzomib demonstrated clinically meaningful renal responses with a favorable tolerability profile in an earlier Phase 2 trial -- -- Renal and autoimmune diseases are k...
2023-12-04 08:58
3768
"No Perchlorate, Yes Non-electrolysis"...CJ FNT Introduces Natural Cysteine
FlavorNrich™ MASTER C L-Cysteine gives a healthier alternative to the market with growing demands for natural cysteine with no perchlorates SEOUL, South Korea, Dec. 4, 2023 /PRNewswire/ -- CJ Food & Nutrition Tech (CJ FNT) launched an online campaign showcasing its FlavorNrich™ MASTER C L-Cystei...
2023-12-04 08:00
1478
Media Tour Witnesses Chinese Modernization in Hainan FTP
HAIKOU, China, Dec. 3, 2023 /PRNewswire/ -- From November 27 to December 1, a group made up of more than 60 reporters, overseas communication officers, and social media personalities got their chance to witness the development of the Hainan Free Trade Port (FTP) up close, as they visited key indu...
2023-12-03 16:07
4037
Week's Top Stories
Most Reposted
LINKDOOD Breaks Language Barriers, Ushering a New Era for Cross-Border Romance
[Picked up by 326 media titles]
2024-04-29 06:00
Dow showcases circular and innovative materials science solutions and industry collaborations at Chinaplas 2024
[Picked up by 292 media titles]
2024-04-30 10:11
Puyuan Fashion Resort 2024: A Grand Unveiling of Global Trends and Local Heritage
[Picked up by 269 media titles]
2024-04-28 09:39
TAILG Makes Grand Appearance at 2024 Asiabike Jakarta, Aiming to Set the Benchmark in Indonesia
[Picked up by 254 media titles]
2024-05-02 01:21
Chinese new energy industry contributes to global green, low-carbon transition
[Picked up by 250 media titles]
2024-04-30 15:13Most Read
Scienjoy Holding Corporation Reports Fiscal Year 2023 Financial Results
2024-04-27 04:30
2937
